Skip to main content

Table 3 HRs and 2-, 3- and 4-year PFS and OS probabilities for patients at high and low risk in the hold-out set for the model with imaging and clinical variables and the model with clinical variables only

From: Full automation of total metabolic tumor volume from FDG-PET/CT in DLBCL for baseline risk assessments

 

PFS

OS

 

N

HR (95% CI)

2-year PFS probability,

% (95% CI)

3-year PFS probability,

% (95% CI)

4-year PFS probability,

% (95% CI)

n

HR (95% CI)

2-year OS probability,

% (95% CI)

3-year OS probability,

% (95% CI)

4-year OS probability,

% (95% CI)

Model with imaging and clinical variables

Low-risk patients

200

Reference

84 (79–90)

82 (76–87)

77 (71–83)

210

Reference

90 (86–94)

89 (85–94)

88 (84–93)

High-risk patients

222

1.87 (1.31–2.67)

68 (62–74)

65 (58–72)

60 (53–67)

212

2.16 (1.37–3.40)

79 (74–85)

76 (70–82)

75 (69–81)

Model with clinical variables only

Low-risk patients

197

Reference

82 (76–87)

78 (73–84)

72 (66–79)

197

Reference

88 (83–92)

86 (81–91)

85 (80–90)

High-risk patients

225

1.38 (0.98–1.96)

70 (64–77)

68 (62–75)

64 (58–71)

225

1.40 (0.90–2.17)

82 (77–87)

80 (75–85)

78 (73–84)

  1. CI Confidence interval, HR Hazard ratio, OS Overall survival, PFS Progression-free survival